Drug Profile


Alternative Names: BTA C585; BTA585

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biomolecular Research Institute; Biota Holdings
  • Developer Aviragen Therapeutics
  • Class Antivirals; Imidazoles; Isoxazoles; Pyrazines; Pyridines; Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Respiratory syncytial virus infections

Most Recent Events

  • 31 Aug 2017 Suspended - Phase-I for Respiratory syncytial virus infections (In volunteers) in USA (PO)
  • 31 Aug 2017 Suspended - Phase-II for Respiratory syncytial virus infections (In volunteers) in United Kingdom (PO)
  • 11 May 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top